Brought to you by 
Bicycle Therapeutics raises £40mm through Series B round; second tranche closed
24 May 2019
Executive Summary
Bicycle Therapeutics Ltd. closed its Series B round, raising £40mm ($52mm) from new investors Vertex Ventures HC (lead), Cambridge Innovation Capital, and Longwood Fund, along with returning backers Novartis Venture Fund, SR One, SV Life Sciences, and Atlas Venture. (Vertex and Cambridge join the board.) Bicycle is developing cancer therapies based on its Bicycles bicyclic peptide platform, and will use the proceeds to advance development of lead preclinical candidate BT1718 for triple-negative breast cancer and non-small cell lung cancer, and to continue studies on additional pipeline projects.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bicycle Therapeutics raises £40mm through Series B round; second tranche closed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice